Meridian Bioscience Stock

Meridian Bioscience Accounts Payable

The Accounts Payable of Meridian Bioscience (VIVO) as of Aug 20, 2026 is 17.76 M USD. In the previous year, Accounts Payable was 11.70 M USD — a change of 51.77% (higher).

Accounts Payable

17.76 MUSD

YoY

51.77%

Last updated:

Accounts Payable of Meridian Bioscience is 2026 17.76 M USD. Accounts Payable of Meridian Bioscience was 2025 11.70 M USD. It decreases by 51.77% higher compared to the previous year.
Access this data via the Eulerpool API

Meridian Bioscience Stock analysis

What does Meridian Bioscience do? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Meridian Bioscience stock

Accounts Payable of Meridian Bioscience is 17.76 M USD in 2026.

Accounts Payable of Meridian Bioscience changed from 11.70 M USD to 17.76 M USD, representing a 51.77% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable Meridian Bioscience since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's Meridian Bioscience historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Meridian Bioscience

All Key Metrics — Meridian Bioscience